Abstract:Two-week courses of either high-dose famotidine or omeprazole, both combined with amoxycillin and tinidazole, are equally effective for eradication of H. pylori infection. In a 2-week triple therapy, metronidazole resistance has no significant impact on eradication rates.
“…Amoxicillin, nitroimidazole and a gastric acid inhibitor Amoxicillin, a nitroimidazole and a gastric acid inhibitor (ANG) were used to treat 1945 subjects in North America (one study, two arms), Asia (seven studies, 17 arms), Australia (one study, two arms) and Europe (15 studies, 36 arms) 33, 40, 41, 46–66 . Most treatment arms used metronidazole (88%) as the nitroimidazole, and omeprazole (67%) as the gastric acid inhibitor; 18% used lansoprazole and 11% used famotidine.…”
Section: Resultsmentioning
confidence: 99%
“…References are reported in the order they are presented in the figure. ANG 33, 40, 41, 47, 47–51, 51–55, 55, 56, 56–61, 61–66 and ACG 38, 62, 67, 70, 70, 91, 91–96, 96, 97, 97, 99, 100, 100–102, 102, 102–104, 104, 104, 105 …”
“…Amoxicillin, nitroimidazole and a gastric acid inhibitor Amoxicillin, a nitroimidazole and a gastric acid inhibitor (ANG) were used to treat 1945 subjects in North America (one study, two arms), Asia (seven studies, 17 arms), Australia (one study, two arms) and Europe (15 studies, 36 arms) 33, 40, 41, 46–66 . Most treatment arms used metronidazole (88%) as the nitroimidazole, and omeprazole (67%) as the gastric acid inhibitor; 18% used lansoprazole and 11% used famotidine.…”
Section: Resultsmentioning
confidence: 99%
“…References are reported in the order they are presented in the figure. ANG 33, 40, 41, 47, 47–51, 51–55, 55, 56, 56–61, 61–66 and ACG 38, 62, 67, 70, 70, 91, 91–96, 96, 97, 97, 99, 100, 100–102, 102, 102–104, 104, 104, 105 …”
“…A recent randomized, controlled trial showed that famotidine and omeprazole, combined with clarithromycin and metronidazole, were equivalent for cure of H. pylori infection [10]. In contrast, other data showed that ranitidine, when used together with amoxicillin and metronidazole, was less effective than omeprazole [12]. In our series, the 1‐week course of LFT plus amoxicillin and clarithromycin yielded acceptably high eradication rates of 85.2 and 88.2% on intention‐to‐treat and per protocol analyses, respectively, which were comparable with those of the LPZ‐based regimen with similar combination of antibiotics.…”
The lafutidine-clarithromycin-amoxicillin therapy yielded satisfactory results for eradicating H. pylori, which was comparable with those of the lansoprazole-based regimen with the same drug combination.
“…Finally, one more study was excluded because it evaluated these therapies as second‐line treatment for previous eradication failures 15 . Therefore, 20 studies finally fulfilled the inclusion criteria and contained data for the planned comparison; 16–35 detailed characteristics of these studies are shown in Table 1.…”
SUMMARYBackground: It is unknown whether proton pump inhibitors are superior to H 2 -receptor antagonists in Helicobacter pylori eradication regimens. Aim: To perform a meta-analysis comparing the efficacy of both antisecretors when co-prescribed with antibiotics. Methods: Randomized clinical trials comparing proton pump inhibitors vs. H 2 -receptor antagonists with the same antibiotics were selected. Data sources included PubMed, the Cochrane Controlled Trials Register and abstracts from congresses up to January 2002. A meta-analysis was performed by combining the odds ratios. Results: Twenty studies fulfilled the inclusion criteria. In the intention-to-treat analysis, the mean eradication
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.